Background: Medulloblastoma is the most common malignant childhood brain tumor, although long-term risks for chronic neurologic health and psychosocial functioning in aging adult survivors are incompletely characterized. Methods: The Childhood Cancer Survivor Study (CCSS) includes 380 five-year survivors of medulloblastoma/primitive neuroectodermal tumor (PNET; median age at follow-up: 30 y, interquartile range 24-36) and sibling comparison (n = 4031). Cumulative incidence of neurologic health conditions was reported. Cox regression models provided hazard ratios (HRs) and 95% CIs. Cross-sectional outcomes were assessed using generalized linear models. Results: Compared with siblings, survivors were at increased risk of late-onset hearing loss (HR: 36.0, 95% CI: 23.6-54.9), stroke (HR: 33.9, 95% CI: 17.8-64.7), seizure (HR: 12.8, 95% CI: 9.0-18.1), poor balance (HR: 10.4, 95% CI: 6.7-15.9), tinnitus (HR: 4.8, 95% CI: 3.5-6.8), and cataracts (HR: 31.8, 95% CI: 16.7-60.5). Temporal/frontal lobe radiotherapy of 50 Gy or more increased risk for hearing loss (HR: 1.9, 95% CI: 1.1-1.3), seizure (HR: 2.1, 95% CI: 1.1-3.9), stroke (HR: 3.5, 95% CI: 1.3-9.1), and tinnitus (HR: 2.0, 95% CI: 1.0-3.9). Survivors were less likely than siblings to earn a college degree (relative risk [RR]: 0.49, 95% CI: 0.39-0.60), marry (RR: 0.35, 95% CI: 0.29-0.42), and live independently (RR: 0.58, 95% CI: 0.52-0.66). Conclusions: Adult survivors of childhood medulloblastoma/PNET demonstrate pronounced risk for hearing impairment, stroke, lower educational attainment, and social independence. Interventions to support survivors should be a high priority.
RCT Entities:
Background: Medulloblastoma is the most common malignant childhood brain tumor, although long-term risks for chronic neurologic health and psychosocial functioning in aging adult survivors are incompletely characterized. Methods: The Childhood Cancer Survivor Study (CCSS) includes 380 five-year survivors of medulloblastoma/primitive neuroectodermal tumor (PNET; median age at follow-up: 30 y, interquartile range 24-36) and sibling comparison (n = 4031). Cumulative incidence of neurologic health conditions was reported. Cox regression models provided hazard ratios (HRs) and 95% CIs. Cross-sectional outcomes were assessed using generalized linear models. Results: Compared with siblings, survivors were at increased risk of late-onset hearing loss (HR: 36.0, 95% CI: 23.6-54.9), stroke (HR: 33.9, 95% CI: 17.8-64.7), seizure (HR: 12.8, 95% CI: 9.0-18.1), poor balance (HR: 10.4, 95% CI: 6.7-15.9), tinnitus (HR: 4.8, 95% CI: 3.5-6.8), and cataracts (HR: 31.8, 95% CI: 16.7-60.5). Temporal/frontal lobe radiotherapy of 50 Gy or more increased risk for hearing loss (HR: 1.9, 95% CI: 1.1-1.3), seizure (HR: 2.1, 95% CI: 1.1-3.9), stroke (HR: 3.5, 95% CI: 1.3-9.1), and tinnitus (HR: 2.0, 95% CI: 1.0-3.9). Survivors were less likely than siblings to earn a college degree (relative risk [RR]: 0.49, 95% CI: 0.39-0.60), marry (RR: 0.35, 95% CI: 0.29-0.42), and live independently (RR: 0.58, 95% CI: 0.52-0.66). Conclusions: Adult survivors of childhood medulloblastoma/PNET demonstrate pronounced risk for hearing impairment, stroke, lower educational attainment, and social independence. Interventions to support survivors should be a high priority.
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Penelope R Brock; Kristin R Knight; David R Freyer; Kathleen C M Campbell; Peter S Steyger; Brian W Blakley; Shahrad R Rassekh; Kay W Chang; Brian J Fligor; Kaukab Rajput; Michael Sullivan; Edward A Neuwelt Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Thomas E Merchant; Ciara J Gould; Xiaoping Xiong; Nicole Robbins; Junhong Zhu; David L Pritchard; Raja Khan; Richard L Heideman; Matthew J Krasin; Larry E Kun Journal: Int J Radiat Oncol Biol Phys Date: 2004-03-15 Impact factor: 7.038
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: James G Gurney; Kirsten K Ness; Marilyn Stovall; Suzanne Wolden; Judy A Punyko; Joseph P Neglia; Ann C Mertens; Roger J Packer; Leslie L Robison; Charles A Sklar Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 6.134
Authors: Barrett D Allen; Munjal M Acharya; Pierre Montay-Gruel; Patrik Goncalves Jorge; Claude Bailat; Benoît Petit; Marie-Catherine Vozenin; Charles Limoli Journal: Radiat Res Date: 2020-12-01 Impact factor: 2.841
Authors: Jeffrey P Gross; Stephanie Powell; Frank Zelko; William Hartsell; Stewart Goldman; Jason Fangusaro; Rishi R Lulla; Natasha Pillay Smiley; John Han-Chih Chang; Vinai Gondi Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: Janet A Deatrick; Lamia P Barakat; George J Knafl; Wendy Hobbie; Sue Ogle; Jill P Ginsberg; Michael J Fisher; Thomas Hardie; Maureen Reilly; Elizabeth Broden; Jennifer Toth; Nicole SanGiacomo; Kathleen A Knafl Journal: J Fam Psychol Date: 2018-04
Authors: Amber Khan; Nidha Mubdi; Amy Budnick; Darren R Feldman; Sharon W Williams; Seema Patel; Emily S Tonorezos Journal: Cancer Date: 2020-01-03 Impact factor: 6.860
Authors: Fiona Schulte; Alicia S Kunin-Batson; Barbara A Olson-Bullis; Pia Banerjee; Matthew C Hocking; Laura Janzen; Lisa S Kahalley; Hayley Wroot; Caitlin Forbes; Kevin R Krull Journal: J Cancer Surviv Date: 2019-10-17 Impact factor: 4.442
Authors: Matthew R Trendowski; Jessica L Baedke; Yadav Sapkota; Lois B Travis; Xindi Zhang; Omar El Charif; Heather E Wheeler; Wendy M Leisenring; Leslie L Robison; Melissa M Hudson; Lindsay M Morton; Kevin C Oeffinger; Rebecca M Howell; Gregory T Armstrong; Smita Bhatia; M Eileen Dolan Journal: Cancer Date: 2021-07-19 Impact factor: 6.860